Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer

BACKGROUND: The use of nivolumab or irinotecan as the third-line treatment for patients with advanced gastric cancer (AGC) remains controversial. METHODS: This study analyzed patients with AGC treated with nivolumab or irinotecan (nivolumab group or irinotecan group, respectively) from May 2016 to A...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Ther Adv Med Oncol
Hoofdauteurs: Ishii, Takahiro, Kawazoe, Akihito, Sasaki, Akinori, Mishima, Saori, Kentaro, Sawada, Nakamura, Yoshiaki, Kotani, Daisuke, Kuboki, Yasutoshi, Taniguchi, Hiroya, Kojima, Takashi, Doi, Toshihiko, Yoshino, Takayuki, Kuwata, Takeshi, Ishii, Genichiro, Shitara, Kohei
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: SAGE Publications 2020
Onderwerpen:
Original Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7370559/
https://ncbi.nlm.nih.gov/pubmed/32733607
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920942377
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items